Calcium Channel
Ca2+ channels; Ca channels
Calcium channel is an ion channel which displays selective permeability to calcium ions. It is sometimes synonymous as voltage-dependent calcium channel, although there are also ligand-gated calcium channels. Voltage-gated calcium (CaV) channels catalyse rapid, highly selective influx of Ca2+ into cells despite a 70-fold higher extracellular concentration of Na+. Some calcium channel blockers have the added benefit of slowing your heart rate, which can further reduce blood pressure, relieve chest pain (angina) and control an irregular heartbeat.
Calcium Channel Isoform Specific Products
All Product Categories
-
Calcium Channel Inhibitors
(597)
View all products
-
Calcium Channel Agonists
(35)
View all products
-
Calcium Channel Antagonists
(210)
View all products
-
Calcium Channel Activators
(92)
View all products
-
Calcium Channel Modulators
(46)
View all products
-
Calcium Channel Chemical
(1)
View all products
-
Calcium Channel Inducers
(12)
View all products
-
Calcium Channel Controls
(10)
View all products
-
Calcium Channel Ligands
(7)
View all products
-
Calcium Channel Related Products (1247)
Related Products (1247)
-
Antibodies (29)
-
Related Compound Screening Libraries (1)
-
Calcium Channel Isoform Comparison
-
PptT-IN-4
0 ImagesCat. No.: HY-149305CAS No.: 2948309-57-5PptT-IN-4 (Compound 3a) is a PptT inhibitor (IC50: 0.71 μM). PptT-IN-4 inhibits Mtb H37Rv with a MIC value of 42 μM. PptT-IN-4 also inhibits hERG, hCav1.2, and hNav1.5 channels with IC50s of 11 μM, 8.1 μM, 6.9 μM respectively.
-
IS4
0 ImagesCat. No.: HY-P11019CAS No.: 3067986-23-3IS4 is a selective CXCR4 competitive antagonist, with an IC50 of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. IS4 is stable in serum and non-cytotoxic. IS4 competitively binds to CXCR4 with CXCL12, thereby inhibiting CXCL12-induced intracellular Ca2+ release and cancer cell migration. IS4 can be used in the research on the prevention of metastasis of breast cancer, prostate cancer, leukemia, and other diseases.
-
Hyperforin
0 ImagesCat. No.: HY-116330CAS No.: 11079-53-1Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.
-
Calcium Channel antagonist 4
0 ImagesCat. No.: HY-156669CAS No.: 687574-49-8Calcium Channel antagonist 4 (compound 189) is an inhibitor of voltage-gated calcium channels with an IC50 value of 5-20μM.
-
RWJ 22108
0 ImagesCat. No.: HY-123435CAS No.: 112769-37-6RWJ 22108 is a bronchoselective calcium channel blocker, with the IC50 of 5.7 nM in calcium-dependent contraction of canine bronchiolar smooth muscle.
-
Sulofenur
0 ImagesCat. No.: HY-106603CAS No.: 110311-27-8Synonyms: Diarylsulfonylurea; LY186641Sulofenur (LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models.
-
Taurolithocholic acid-d4-1 sodium
0 ImagesCat. No.: HY-113308AS2Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
-
14-Deoxyandrographolide (Standard)
0 Images14-Deoxyandrographolide (Standard) is the analytical standard of 14-Deoxyandrographolide. 14-Deoxyandrographolide is a diterpene with calcium channel blocking activity and acts as a uterine smooth muscle relaxant. 14-Deoxyandrographolide stimulates the release of nitric oxide (NO) in endothelial cells. 14-Deoxyandrographolide gradually desensitizes liver cells to TNF-α mediated apoptosis by inducing the release of TNFRSF1A.
-
Halofuginone hydrochloride (Standard)
0 ImagesCat. No.: HY-N1584BRCAS No.: 1217623-74-9Synonyms: RU-19110 hydrochloride (Standard)Halofuginone hydrochloride (Standard) (RU-19110 hydrochloride (Standard)) is the analytical standard of Halofuginone hydrochloride (HY-N1584B). This product is intended for research and analytical applications. Halofuginone hydrochloride (RU-19110 hydrochloride), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrochloride is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrochloride is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrochloride has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
-
α-Obscurine derivative-1
0 ImagesCat. No.: HY-177955CAS No.: 3093625-46-5α-Obscurine derivative-1 (Compound 7) is a α-Obscurine (HY-134036) derivative. α-Obscurine derivative-1 inhibits CaV3.1 ion channel current with an IC50 of 0.19 μM. α-Obscurine derivative-1 can be used in the research of neurological disorders.
-
Propiverine-d7 hydrochloride
0 ImagesCat. No.: HY-116408ASPropiverine-d7 (hydrochloride) is the deuterium labeled Propiverine hydrochloride. Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties. Propiverine hydrochloride can be used for the research of overactive blaqdder and urinary incontinence.
-
Mioflazine
0 ImagesCat. No.: HY-U00049CAS No.: 79467-23-5Mioflazine is an orally active nucleoside transport inhibitor with sleep-improving activity. Mioflazine significantly improves cardiac survival after global cardiac ischemia. Mioflazine inhibits nucleoside uptake Mioflazine does not exhibit inotropic effects during induction and nursing.
-
Antiallergic agent-5
0 ImagesCat. No.: HY-180165Antiallergic agent-5 (Compound 4f) is an antiallergic agent. Antiallergic agent-5 suppresses Ca2+ influx. Antiallergic agent-5 suppresses IgE/Ag-induced release of both IL-6 and TNF-α. Antiallergic agent-5 inhibits mast cell degranulation. Antiallergic agent-5 attenuates passive cutaneous anaphylaxis in mice and reduces vascular leakage.
-
BGC-201259
0 ImagesCat. No.: HY-107047CAS No.: 444667-97-4Synonyms: RS-1259BGC-201259 (RS-1259) is an orally active inhibitor that simultaneously targets acetylcholinesterase (AChE) (IC50 = 101 nM) and serotonin transporter (SERT) (IC50 = 42 nM). BGC-201259 inhibits 5-HT receptor with an IC50 of 90 nM. BGC-201259 exhibits strong weak activity against the NA transporter (IC50 = 7.7 μM), L-type calcium channel (IC50 = 3.6 μM), σ receptor (IC50 = 2 μM), and sodium channel (IC50 = 5.1 μM). BGC-201259 demonstrates synergistic potential in improving cognitive and emotional symptoms by balancing the inhibition of these two targets. BGC-201259 can be used in research on Alzheimer's disease.
-
SL-870495
0 ImagesCat. No.: HY-125093CAS No.: 120560-67-0SL-870495 is a calcium antagonist targeting L-type calcium channels. SL-870495 is promising for research of cardiovascular diseases such as hypertension and angina pectoris.
-
Aladorian sodium
0 ImagesCat. No.: HY-119850ACAS No.: 1233219-11-8Synonyms: ARM036 sodium; S44121 sodiumAladorian (ARM036; S44121) sodium is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian sodium stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian sodium improves cardiomyocyte Ca2+ homeostasis independent of dystrophin restoration. Aladorian sodium attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian sodium can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy.
-
ATI22-107
0 ImagesCat. No.: HY-126763CAS No.: 681816-57-9ATI22-107 is a dual-pharmacophore compound designed to simultaneously inhibit cardiac phosphodiesterase (PDE-III) and L-type calcium channels (LTCC), with activity that has specific effects on calcium cycling and contractility in cat ventricular myocytes and trabeculae.
-
Multi-target kinase-IN-6
0 ImagesCat. No.: HY-178344Multi-target kinase-IN-6 is a Multiple target kinase inhibitor. Multi-target kinase-IN-6 can inhibit cardiac RyR2- and NaV1.5-channels but stimulate SERCA2a pump activity. Multi-target kinase-IN-6 can be used for the research of cardiovascular disease, such as heart failure.
-
20:4 Lyso PI
0 ImagesCat. No.: HY-150187CAS No.: 1246430-04-520:4 Lyso PI acts as an activator of GPR55 and RhoA. 20:4 Lyso PI activates the GPR55-RhoA-ROCK pathway, thereby inducing morphological changes, cytoskeleton assembly, cell rounding and stress fiber formation. 20:4 Lyso PI can be used in research related to diseases such as those of the nervous system.
